MICROPORT NEUROTECH LIMITED MicroPort NeuroTech Limited Stock
Equities
2172
KYG6083E1098
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.12 HKD | +3.40% |
|
+1.33% | -25.49% |
| Sales 2024 * | 868M 120M 938M | Sales 2025 * | 1.22B 168M 1.32B | Capitalization | 4.92B 680M 5.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 233M 32.18M 252M | Net income 2025 * | 309M 42.67M 334M | EV / Sales 2024 * | 5.67 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.04 x |
| P/E ratio 2024 * |
21.1
x | P/E ratio 2025 * |
15.9
x | Employees | 571 |
| Yield 2024 * |
0.71% | Yield 2025 * |
0.77% | Free-Float | 31.07% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.40% | ||
| 1 week | +1.33% | ||
| 1 month | -1.83% | ||
| 3 months | -7.13% | ||
| 6 months | -23.62% | ||
| Current year | -25.49% |
1 week
8.24
10.00
1 month
8.2410.00
Current year
8.0412.76
1 year
8.0414.60
3 years
8.0426.80
5 years
8.0426.80
10 years
8.0426.80
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Yong Xie
CEO | Chief Executive Officer | 48 | 12-03-31 |
Zhuo Ping Hou
DFI | Director of Finance/CFO | 46 | 18-05-31 |
Zao Li Wu
ADM | Chief Administrative Officer | 41 | 12-12-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhao Hua Chang
CHM | Chairman | 61 | Nov. 02 |
Chi Hung Siu
BRD | Director/Board Member | 53 | 22-06-21 |
Xia Wu
BRD | Director/Board Member | 43 | 21-11-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 9.12 | +3.40% | 4,911,000 |
| 24-05-30 | 8.82 | +1.97% | 1,984,000 |
| 24-05-29 | 8.65 | -1.48% | 1,272,000 |
| 24-05-28 | 8.78 | -3.30% | 655,000 |
| 24-05-27 | 9.08 | +0.89% | 859,000 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am EDT
More quotes
MicroPort NeuroTech Ltd is a China-based investment holding company. The company is principally engaged in the research and development, manufacturing and sales of neuro-interventional medical devices. The Company's main products include embolization coils, flow-diverting stents and stent grafts. The Company's products mainly cover three major areas of neurovascular diseases, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The Company mainly operates its businesses in the domestic and overseas markets.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.446
CNY
Average target price
12.94
CNY
Spread / Average Target
+53.16%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.49% | 680M | |
| +13.73% | 130B | |
| -8.17% | 10.99B | |
| -4.33% | 8.35B | |
| +41.80% | 5.67B | |
| -21.94% | 4.72B | |
| +7.81% | 3.42B | |
| -10.26% | 2.76B | |
| -10.29% | 2.11B | |
| -13.58% | 1.92B |
- Stock Market
- Equities
- 2172 Stock
